Gestational trophoblastic disease: does central nervous system chemoprophylaxis have a role?
In the UK there are standardized surveillance procedures for gestational trophoblastic disease. However, there are differences in practice between the two treatment centres in terms of definition of persistent gestational trophoblastic disease, prognostic risk assessment and chemotherapeutic regimens. The role of prophylactic chemotherapy for cerebral micrometastatic disease in persistent gestational trophoblastic disease is unclear. We have analysed the outcome of 69 patients with lung metastases who elsewhere might have received prophylactic intrathecal chemotherapy. Of the 69 patients, 67 received intravenous chemotherapy only. The other two patients had cerebral metastases at presentation. One patient who received only intravenous chemotherapy subsequently developed a cerebral metastasis, but this patient's initial treatment was compromised by non-compliance. This experience supports our current policy of not treating patients with pulmonary metastases, without clinical evidence of central nervous system (CNS) involvement, with prophylactic intrathecal therapy.
Gillespie
A M
AM
Gestational Trophoblastic Disease Screening and Treatment Centre, Yorkshire Cancer Research, Department of Clinical Oncology, Weston Park Hospital, Sheffield.
Siddiqui
N
N
Coleman
R E
RE
Hancock
B W
BW
D000293:Adolescent; D000328:Adult; D000931:Antidotes / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D003609:Dactinomycin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000556:secondary*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010349:Patient Compliance; D011247:Pregnancy; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D014328:Trophoblastic Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D014594:Uterine Neoplasms / Q000473:pathology*
D000931:Antidotes; D003609:Dactinomycin; D005047:Etoposide; D002955:Leucovorin; D008727:Methotrexate